# HP Inc: financial statements, quarterly

HPQ · NYSE · CIK 47217 · [Technology](/sectors/technology.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/hpq.md) · [Financials](/companies/hpq/financials.md) · [Filings](/companies/hpq/filings.md) · [Insiders](/companies/hpq/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hpq/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [13.8 d](/filings/0000047217-25-000071.md) | [13.2](/filings/0000047217-25-000025.md) | [12.8](/filings/0000047217-25-000043.md) | [13.5](/filings/0000047217-25-000063.md) | [14.1 d](/filings/0000047217-25-000071.md) | [13.5](/filings/0000047217-26-000011.md) | [13.2](/filings/0000047217-26-000029.md) | [13.9](/filings/0000047217-26-000051.md) | [14.6 d](/filings/0000047217-25-000071.md) | [14.4](/filings/0000047217-26-000011.md) | [14.4](/filings/0000047217-26-000029.md) | [15.7](/filings/0000047217-26-000051.md) |
| Cost of revenue | $bn | [10.8 d](/filings/0000047217-25-000071.md) | [10.3](/filings/0000047217-25-000025.md) | [9.8](/filings/0000047217-25-000043.md) | [10.6](/filings/0000047217-25-000063.md) | [11.1 d](/filings/0000047217-25-000071.md) | [10.7](/filings/0000047217-26-000011.md) | [10.5](/filings/0000047217-26-000029.md) | [11.1](/filings/0000047217-26-000051.md) | [11.7 d](/filings/0000047217-25-000071.md) | [11.6](/filings/0000047217-26-000011.md) | [11.4](/filings/0000047217-26-000029.md) | [12.7](/filings/0000047217-26-000051.md) |
| Gross profit | $bn | [3.0 d](/filings/0000047217-25-000071.md) | [2.9](/filings/0000047217-25-000025.md) | [3.0](/filings/0000047217-25-000043.md) | [2.9](/filings/0000047217-25-000063.md) | [3.0 d](/filings/0000047217-25-000071.md) | [2.8](/filings/0000047217-26-000011.md) | [2.7](/filings/0000047217-26-000029.md) | [2.9](/filings/0000047217-26-000051.md) | [3.0 d](/filings/0000047217-25-000071.md) | [2.8](/filings/0000047217-26-000011.md) | [3.0](/filings/0000047217-26-000029.md) | [2.9](/filings/0000047217-26-000051.md) |
| Research and development | $bn | [0.4 d](/filings/0000047217-25-000071.md) | [0.4](/filings/0000047217-25-000025.md) | [0.4](/filings/0000047217-25-000043.md) | [0.4](/filings/0000047217-25-000063.md) | [0.4 d](/filings/0000047217-25-000071.md) | [0.4](/filings/0000047217-26-000011.md) | [0.4](/filings/0000047217-26-000029.md) | [0.4](/filings/0000047217-26-000051.md) | [0.4 d](/filings/0000047217-25-000071.md) | [0.4](/filings/0000047217-26-000011.md) | [0.4](/filings/0000047217-26-000029.md) | [0.4](/filings/0000047217-26-000051.md) |
| Selling, general and administrative | $bn | [1.3 d](/filings/0000047217-25-000071.md) | [1.4](/filings/0000047217-25-000025.md) | [1.5](/filings/0000047217-25-000043.md) | [1.4](/filings/0000047217-25-000063.md) | [1.4 d](/filings/0000047217-25-000071.md) | [1.5](/filings/0000047217-26-000011.md) | [1.5](/filings/0000047217-26-000029.md) | [1.5](/filings/0000047217-26-000051.md) | [1.4 d](/filings/0000047217-25-000071.md) | [1.5](/filings/0000047217-26-000011.md) | [1.5](/filings/0000047217-26-000029.md) | [1.5](/filings/0000047217-26-000051.md) |
| Operating income | $bn | [1.0 d](/filings/0000047217-25-000071.md) | [0.9](/filings/0000047217-25-000025.md) | [1.0](/filings/0000047217-25-000043.md) | [0.9](/filings/0000047217-25-000063.md) | [1.0 d](/filings/0000047217-25-000071.md) | [0.8](/filings/0000047217-26-000011.md) | [0.7](/filings/0000047217-26-000029.md) | [0.7](/filings/0000047217-26-000051.md) | [1.0 d](/filings/0000047217-25-000071.md) | [0.8](/filings/0000047217-26-000011.md) | [0.6](/filings/0000047217-26-000029.md) | [0.9](/filings/0000047217-26-000051.md) |
| Interest expense | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $bn | [(0.1) d](/filings/0000047217-25-000071.md) | [0.2](/filings/0000047217-25-000025.md) | [0.2](/filings/0000047217-25-000043.md) | [0.2](/filings/0000047217-25-000063.md) | [(0.0) d](/filings/0000047217-25-000071.md) | [0.1](/filings/0000047217-26-000011.md) | [0.1](/filings/0000047217-26-000029.md) | [(0.1)](/filings/0000047217-26-000051.md) | [0.0 d](/filings/0000047217-25-000071.md) | [0.1](/filings/0000047217-26-000011.md) | [0.0](/filings/0000047217-26-000029.md) | [0.1](/filings/0000047217-26-000051.md) |
| Net income | $bn | [1.0 d](/filings/0000047217-25-000071.md) | [0.6](/filings/0000047217-25-000063.md) | [0.6](/filings/0000047217-25-000063.md) | [0.6](/filings/0000047217-25-000063.md) | [0.9 d](/filings/0000047217-25-000071.md) | [0.6](/filings/0000047217-26-000051.md) | [0.4](/filings/0000047217-26-000051.md) | [0.8](/filings/0000047217-26-000051.md) | [0.8 d](/filings/0000047217-25-000071.md) | [0.5](/filings/0000047217-26-000051.md) | [0.5](/filings/0000047217-26-000051.md) | [0.7](/filings/0000047217-26-000051.md) |
| Diluted EPS | $ per share | not reported | [0.62](/filings/0000047217-25-000025.md) | [0.61](/filings/0000047217-25-000043.md) | [0.65](/filings/0000047217-25-000063.md) | not reported | [0.59](/filings/0000047217-26-000011.md) | [0.42](/filings/0000047217-26-000029.md) | [0.80](/filings/0000047217-26-000051.md) | not reported | [0.58](/filings/0000047217-26-000011.md) | [0.49](/filings/0000047217-26-000029.md) | [0.71](/filings/0000047217-26-000051.md) |
| Basic EPS | $ per share | not reported | [0.63](/filings/0000047217-25-000025.md) | [0.62](/filings/0000047217-25-000043.md) | [0.65](/filings/0000047217-25-000063.md) | not reported | [0.60](/filings/0000047217-26-000011.md) | [0.43](/filings/0000047217-26-000029.md) | [0.81](/filings/0000047217-26-000051.md) | not reported | [0.59](/filings/0000047217-26-000011.md) | [0.49](/filings/0000047217-26-000029.md) | [0.72](/filings/0000047217-26-000051.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [3.1](/filings/0000047217-24-000080.md) | [2.3](/filings/0000047217-24-000024.md) | [2.4](/filings/0000047217-24-000041.md) | [2.8](/filings/0000047217-24-000070.md) | [3.2](/filings/0000047217-25-000071.md) | [2.9](/filings/0000047217-25-000025.md) | [2.7](/filings/0000047217-25-000043.md) | [2.9](/filings/0000047217-25-000063.md) | [3.7](/filings/0000047217-26-000051.md) | [3.2](/filings/0000047217-26-000011.md) | [3.7](/filings/0000047217-26-000029.md) | [4.2](/filings/0000047217-26-000051.md) |
| Current assets | $bn | [18.0](/filings/0000047217-24-000080.md) | [16.9](/filings/0000047217-24-000024.md) | [18.6](/filings/0000047217-24-000041.md) | [19.3](/filings/0000047217-24-000070.md) | [20.8](/filings/0000047217-25-000071.md) | [19.8](/filings/0000047217-25-000025.md) | [19.5](/filings/0000047217-25-000043.md) | [20.6](/filings/0000047217-25-000063.md) | [22.5](/filings/0000047217-26-000051.md) | [22.2](/filings/0000047217-26-000011.md) | [24.0](/filings/0000047217-26-000029.md) | [26.7](/filings/0000047217-26-000051.md) |
| Total assets | $bn | [37.0](/filings/0000047217-24-000080.md) | [35.8](/filings/0000047217-24-000024.md) | [37.4](/filings/0000047217-24-000041.md) | [38.1](/filings/0000047217-24-000070.md) | [39.9](/filings/0000047217-25-000071.md) | [38.9](/filings/0000047217-25-000025.md) | [38.8](/filings/0000047217-25-000043.md) | [39.9](/filings/0000047217-25-000063.md) | [41.8](/filings/0000047217-26-000051.md) | [41.5](/filings/0000047217-26-000011.md) | [42.9](/filings/0000047217-26-000029.md) | [45.7](/filings/0000047217-26-000051.md) |
| Current liabilities | $bn | [24.5](/filings/0000047217-24-000080.md) | [23.9](/filings/0000047217-24-000024.md) | [24.8](/filings/0000047217-24-000041.md) | [27.0](/filings/0000047217-24-000070.md) | [28.7](/filings/0000047217-25-000071.md) | [27.4](/filings/0000047217-25-000025.md) | [26.6](/filings/0000047217-25-000043.md) | [27.9](/filings/0000047217-25-000063.md) | [29.3](/filings/0000047217-26-000051.md) | [29.3](/filings/0000047217-26-000011.md) | [30.2](/filings/0000047217-26-000029.md) | [34.0](/filings/0000047217-26-000051.md) |
| Long-term debt | $bn | [9.3](/filings/0000047217-24-000080.md) | [9.3](/filings/0000047217-24-000024.md) | [9.3](/filings/0000047217-24-000041.md) | [8.2](/filings/0000047217-24-000070.md) | [8.3](/filings/0000047217-25-000071.md) | [8.3](/filings/0000047217-25-000025.md) | [9.3](/filings/0000047217-25-000043.md) | [8.8](/filings/0000047217-25-000063.md) | [8.8](/filings/0000047217-26-000051.md) | [8.8](/filings/0000047217-26-000011.md) | [8.9](/filings/0000047217-26-000029.md) | [7.9](/filings/0000047217-26-000051.md) |
| Current portion of debt | $bn | [0.2](/filings/0000047217-24-000080.md) | [0.2](/filings/0000047217-24-000024.md) | [0.2](/filings/0000047217-24-000041.md) | [1.3](/filings/0000047217-24-000070.md) | [1.4](/filings/0000047217-25-000071.md) | [1.4](/filings/0000047217-25-000025.md) | [1.4](/filings/0000047217-25-000043.md) | [0.8](/filings/0000047217-25-000063.md) | [0.8](/filings/0000047217-26-000051.md) | [0.8](/filings/0000047217-26-000011.md) | [0.8](/filings/0000047217-26-000029.md) | [1.3](/filings/0000047217-26-000051.md) |
| Shareholders' equity | $bn | [(1.1)](/filings/0000047217-25-000071.md) | [(1.6)](/filings/0000047217-25-000063.md) | [(0.9)](/filings/0000047217-25-000063.md) | [(1.4)](/filings/0000047217-25-000063.md) | [(1.3)](/filings/0000047217-26-000051.md) | [(1.1)](/filings/0000047217-26-000051.md) | [(1.3)](/filings/0000047217-26-000051.md) | [(0.9)](/filings/0000047217-26-000051.md) | [(0.3)](/filings/0000047217-26-000051.md) | [(0.8)](/filings/0000047217-26-000051.md) | [(0.1)](/filings/0000047217-26-000051.md) | [(0.1)](/filings/0000047217-26-000051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,975 d](/filings/0000047217-25-000071.md) | [121](/filings/0000047217-25-000025.md) | [581 d](/filings/0000047217-25-000043.md) | [1,424 d](/filings/0000047217-25-000063.md) | [1,623 d](/filings/0000047217-25-000071.md) | [374](/filings/0000047217-26-000011.md) | [38.0 d](/filings/0000047217-26-000029.md) | [1,661 d](/filings/0000047217-26-000051.md) | [1,624 d](/filings/0000047217-25-000071.md) | [383](/filings/0000047217-26-000011.md) | [926 d](/filings/0000047217-26-000029.md) | [1,735 d](/filings/0000047217-26-000051.md) |
| Capital expenditure | $m | [134 d](/filings/0000047217-25-000071.md) | [158](/filings/0000047217-25-000025.md) | [119 d](/filings/0000047217-25-000043.md) | [162 d](/filings/0000047217-25-000063.md) | [153 d](/filings/0000047217-25-000071.md) | [302](/filings/0000047217-26-000011.md) | [183 d](/filings/0000047217-26-000029.md) | [215 d](/filings/0000047217-26-000051.md) | [197 d](/filings/0000047217-25-000071.md) | [233](/filings/0000047217-26-000011.md) | [170 d](/filings/0000047217-26-000029.md) | [187 d](/filings/0000047217-26-000051.md) |
| Dividends paid | $m | [260 d](/filings/0000047217-25-000071.md) | [275](/filings/0000047217-25-000025.md) | [269 d](/filings/0000047217-25-000043.md) | [268 d](/filings/0000047217-25-000063.md) | [263 d](/filings/0000047217-25-000071.md) | [273](/filings/0000047217-26-000011.md) | [273 d](/filings/0000047217-26-000029.md) | [272 d](/filings/0000047217-26-000051.md) | [270 d](/filings/0000047217-25-000071.md) | [277](/filings/0000047217-26-000011.md) | [274 d](/filings/0000047217-26-000029.md) | [274 d](/filings/0000047217-26-000051.md) |
| Share repurchases | $m | [0.0 d](/filings/0000047217-25-000071.md) | [500](/filings/0000047217-25-000025.md) | [100](/filings/0000047217-25-000043.md) | [600](/filings/0000047217-25-000063.md) | [900 d](/filings/0000047217-25-000071.md) | [100](/filings/0000047217-26-000011.md) | [100](/filings/0000047217-26-000029.md) | [200](/filings/0000047217-26-000051.md) | [500 d](/filings/0000047217-25-000071.md) | [325](/filings/0000047217-26-000011.md) | [100](/filings/0000047217-26-000029.md) | [300](/filings/0000047217-26-000051.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-01-31) | Q2 FY2023 (2023-04-30) | Q3 FY2023 (2023-07-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [996](/filings/0000047217-24-000024.md) | [998](/filings/0000047217-24-000041.md) | [1,002](/filings/0000047217-24-000070.md) | [1,002](/filings/0000047217-25-000025.md) | [990](/filings/0000047217-25-000043.md) | [990](/filings/0000047217-25-000063.md) | [957](/filings/0000047217-26-000011.md) | [956](/filings/0000047217-26-000029.md) | [954](/filings/0000047217-26-000051.md) | [932](/filings/0000047217-26-000011.md) | [925](/filings/0000047217-26-000029.md) | [927](/filings/0000047217-26-000051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 901,790,969 at 2026-08-19, from the cover of the [10-Q filed 2026-08-27](/filings/0000047217-26-000051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.